ArriVent BioPharma, Inc. (AVBP)
2025-06-30 | ||||
|---|---|---|---|---|
| Unrealized gain (loss) on marketable securities | -1 | |||
| Total other comprehensive gain (loss) | -1 | |||
| Research and development | 27,720 | |||
| General and administrative | 5,903 | |||
| Total operating expenses | 33,623 | |||
| Operating loss | -33,623 | |||
| Interest and investment income | 2,224 | |||
| Net loss | -31,399 | |||
| Total comprehensive loss | -31,400 | |||
| Earnings per share, basic | -0.9 | |||
| Earnings per share, diluted | -0.9 | |||
| Weighted average number of shares outstanding, basic | 35,006,114 | |||
| Weighted average number of shares outstanding, diluted | 35,006,114 | |||